Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NASDAQ | USD | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| OTC Markets | USD | Delayed | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
By Michael Erman and Patrick Wingrove NEW YORK (Reuters) - Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments...
By Natalie Grover and Maggie Fick LONDON (Reuters) -GSK chief executive Emma Walmsley on Wednesday made replenishing the drugmaker's pipeline of vaccines and therapies her...
By Maggie Fick and Natalie Grover (Reuters) - GSK on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix and...
This market has reached a once-in-two-year turning point. And it’s made our favorite income investments—closed-end funds (CEFs)—terrific contrarian...
Genome sequencing solutions company Illumina (NASDAQ:ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused shares to spiral down...
Cost of sequencing a single human genome has fallen from $100 million to $600 since 2001 Illumina’s new machines can further drop the cost to under $200 Illumina won an...
AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
| Average | 76.67 (+20.70% Upside) |
| High | 88.00 |
| Low | 65.00 |
| Price | 63.52 |
| No. of Analysts | 6 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Sell | Sell | Strong Sell | Buy |
| Technical Indicators | Sell | Sell | Buy | Strong Sell | Buy |
| Summary | Neutral | Sell | Neutral | Strong Sell | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 128.64 | 129.55 | 127.78 | -1.17 | -0.90% | 1.38M | NYSE | |||
| 82.33 | 83.80 | 82.14 | -3.19 | -3.73% | 14.13M | NASDAQ | |||
| 83.68 | 86.28 | 83.22 | -2.41 | -2.80% | 52.81M | NASDAQ | |||
| 194.76 | 198.17 | 189.92 | +4.78 | +2.52% | 185.21M | NASDAQ | |||
| 61.08 | 62.17 | 60.11 | -2.95 | -4.61% | 12.36M | NYSE | |||
| 41.28 | 41.59 | 40.90 | -0.23 | -0.55% | 15.52M | NYSE | |||
| 3.16 | 3.36 | 2.79 | +0.15 | +4.98% | 76.36M | NYSE | |||
| 229.44 | 230.26 | 228.04 | -0.69 | -0.30% | 3.24M | NYSE | |||
| 28.72 | 29.32 | 28.47 | -0.35 | -1.20% | 7.48M | NASDAQ | |||
| 23.86 | 24.88 | 21.77 | +1.61 | +7.24% | 8.53M | NYSE | |||
| 163.36 | 164.85 | 163.10 | -1.25 | -0.76% | 7.01M | NYSE | |||
| 27.89 | 28.09 | 27.08 | +0.41 | +1.49% | 21.03M | NYSE | |||
| 136.18 | 136.32 | 134.95 | -0.76 | -0.56% | 4.83M | NYSE | |||
| 151.73 | 153.10 | 150.78 | -2.77 | -1.79% | 67.99M | NASDAQ | |||
| 11.96 | 12.13 | 11.60 | +0.34 | +2.93% | 26.10M | NASDAQ |